Colegio Argentino de Cardioangiólogos Intervencionistas Revista Argentina de Cardioangiología intervencionista 2250-7531 2313-9307 5 01 2014 4- 20 Revascularization strategies for patients with multiple vessel coronary disease and unprotected left main. A prospective, multicenter and controlled Argentina registry with a cobalt-chromium rapamycin eluting stent, FIREBIRD 2™: protocol design and methods of the ERACI IV Registry 0019 0025 EN Alfredo E Rodríguez Centro de Estudios en Cardiología Intervencionista. Sanatorio Otamendi y Miroli. CABA, Argentina Carlos Fernández-Pereira Clínica IMA., Adrogué, Buenos Aires, Argentina Omar Santaera Clínica Privada Provincial. Merlo, Buenos Aires, Argentina Miguel Larribau Hospital Español. Godoy Cruz, Mendoza, Argentina Carlos Haiek Sanatorio de la Trinidad. Quilmes, Buenos Aires, Argentina Ricardo Sarmiento Hospital El Cruce. Florencio Varela, Buenos Aires, Argentina Juan Mieres Sanatorio Las Lomas. San Isidro, Buenos Aires, Argentina Juan Lloveras Sanatorio San Miguel. San Miguel, Buenos Aires, Argentina Antonio Pocoví Centro Médico el Talar. Tigre, Buenos Aires, Argentina Oscar Carlevaro Hospital Militar Central. CABA, Argentina Ignacio Rifourcat Instituto de Diagnóstico y Tratamiento de Afecciones Cardiovasculares. La Plata, Buenos Aires, Argentina Jonathan ChenMicroport Inc. Shangai, China Kefei Zheng Microport Inc. Shangai, China Alfredo M Rodríguez-GranilloCentro de Estudios en Cardiología Intervencionista. CABA, Argentina David Antoniucci Careggi Ospedale. Florencia, Italia; on behalf of ERACI IV Investigators The ERACI IV Registry is a multicenter and prospective open label study that evaluates the cobalt-chromium alloy sirolimus eluting stent Firebird 2™ for the treatment of patients with multiple vessel coronary artery disease and indication for revascularization. 225 patients were evaluated and included in the registry. Patients inclusion criteria are acute coronary syndromes, excluding ST elevation myocardial infarction (MI), reference vessel diameter >2.5 mm and target lesion diameter stenosis ≥70%. Exclusion criteria were poor left ventricular ejection fraction, previous treatment with drug eluting stent (DES) in an epicardial vessel or contraindication to ASA or thienopyridines. All patients signed an informed consent form according to the National Direction of Personal Data from Argentina following the current law. All data will be incorporate to a database by an electronic case report form. Primary end-point was to know the incidence of cardiovascular events defined as any cause of death, MI, cerebrovascular accident (CVA) and target lesion revascularization (TLR), compared with ERACI III population (Cypher™ and Taxus™ arm and by-pass arm) at 30 days, 6 and 12 months of follow-up. Secondary endpoints includes incidence of target lesion failure (TLF) defined as any ischemia driven revascularization of the target lesion, cardiac death, MI and TLR; incidence of Target vessel revascularization (TVR) and stent thrombosis, according to Academic Research Consortium (A.R.C.) definition. An independent clinical events committee will adjudicate adverse events. DES, multiple vessel disease, unprotected left main http://www.raci.com.ar/contenido/art.php?recordID=MTY5 http://recursos.meducatium.com.ar/contenido/articulos/2400190025_169/pdf/2400190025.pdf